Business Wire

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Hosted on MSN

FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Healio

FDA approves first TAVR platform to treat severe asymptomatic aortic stenosis

Please provide your email address to receive an email when new articles are posted on . A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards ...
Healio

TAVR for asymptomatic severe aortic stenosis superior to surveillance regardless of age

Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...
BioWorld

Edwards seeks a TAVR two-fer in Medicare coverage petition

Edwards Lifesciences Corp., of Irvine, Calif., petitioned the Centers for Medicare & Medicaid Services to revise the Medicare coverage policy for transcatheter aortic valve replacement (TAVR) devices ...
Seeking Alpha

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...